ClinicalTrials.gg
RecruitingNCT07338539BIO-SHORTUpdated May 18, 2026

BIO-SHORT: Hypofractionated RT for Poor-Prognosis GBM

An interventional study of Standard radiotherapy using hypofractionated RT and Experimental Arm Intervention in Glioma, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Tata Memorial Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Glioma with a site in India — 8 open to participants now, 8 under way, none of them phase 3. Glioma · India.

Started
2025
with 2 others
No phase
4 of 19
3 open now
Registered
14th of 19
by date
Lead sponsor
7 of 19
Tata Memorial Centre

Among the 19 studies in Glioma with a site in India, this one is one of 3 that started in 2025, is one of 4 with no phase, and was the 14th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

8 of the 19 studies in Glioma with a site in India are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Glioma with a site in India, or all of them as a file.
02

Study summary

High grade gliomas, particularly glioblastoma, are among the most aggressive brain tumors and are associated with poor outcomes despite standard treatment. Many patients, especially older adults or those with poor general health, are not suitable for surgery and have a life expectancy of less than 12 months. Current standard includes a shortened course of radiotherapy (over 3 weeks) combined with chemotherapy using temozolomide (TMZ), which offers limited survival benefits. This study aims to explore whether delivering radiotherapy in a shorter duration (1 or 2 weeks) at a higher dose, guided by advanced imaging with a PET scan, can improve survival in this group of patients. PET scans help identify the most active parts of the tumor, which aids in targeting of these areas more precisely, potentially improving outcomes while reducing harm to healthy brain tissue. This study will randomly assign 116 eligible patients into two groups:

  • One group will receive the current standard of care (3-week radiotherapy + TMZ).
  • The other group will receive PET-guided radiotherapy over a shorter duration (either 5 or 10 sessions) at a higher dose, alongside TMZ.

The primary goal is to compare overall survival at one year between the two groups. The study will also assess how the disease progresses, side effects of treatment, and the impact on patients' quality of life. The study will be conducted over a total period of 6 years, including 4 years for patient enrolment and 2 years of follow-up. Participation in the study is entirely voluntary, and all patients will undergo an informed consent process. The study has been designed to follow all applicable ethical and regulatory guidelines. The results may help establish a more effective and convenient treatment option for patients with aggressive brain tumors and poor prognosis.

Read the detailed description

Introduction:

Glioblastoma Multiforme(GBM) is the most common malignant primary brain tumor which is uniformly fatal with dismal long term survival rates despite aggressive multimodality therapy. A large proportion of the patients are elderly, presenting at over 65 years of age and their treatment is associated with even more inferior outcomes. Treatment of such elderly patients with typical normo-fractionated Radiotherapy (RT) {1.8-2Gy per fractionation} over 6-6.5 weeks leads to unnecessary protraction of treatment, unduly encumbering patients and their caregivers. Randomised trials and subsequent meta-analyses have shown that hypo-fractionated RT ( typically delivered over 2 -3 weeks ) achieves similar survival as longer 6 week schedules in elderly patients in poor general condition. Addition of Temozolomide based chemotherapy was subsequently shown to improve survival and in current practice hypo-ractionated short course RT(hypo-RT) with TMZ represents the most optimal management of GBM in the elderly achieving a median survival in the vicinity of 6-9 months. Similar survival has been reported in institutional series in poor prognosis High Grade Glioma. Cumulatively, all the data serve as a relatively homogenous point for providing benchmark outcomes which may be used to improve survival by means of treatment intensification and optimisation of the HypoRT -TMZ backbone in this setting.

One of the most tangible ways in which outcomes can be improved pertains to the usage of a higher cumulative RT dose. Retrospective institutional data suggest that normo-fractionated schedules (59.4Gy/33#) delivered in fit elderly individuals are associated with survival benefit. Concurrent data shows that similar increase in median survival to 14-15 months is achievable by the usage of 3 week hypofractionated regimens which are iso-effective to the Stupp regimen. Further safe reduction to a 2 week schedule has been shown in a recent trial using proton therapy and Positron Emission Tomography (PET) guided sub-volume dose escalation. The reduction of dose to the normal brain has shown to be more pragmatically achievable in a recent trial incorporating reduced margins (5mm as opposed to 1.5 -2 cm) for microscopic disease and photon based fractionated radiosurgery which achieved a median survival of 14.8 months with no compromised survival due to marginal recurrences. Overall there is a need for a pragmatic trial incorporating an abbreviated schedule of photon based hypo-fractionated RT (5 fractions/10 fractions) in poor prognosis High Grade Glioma (HGG) using reduced margins and PET based biological sub-volume boosting to deliver adequate doses to the gross tumor and minimise surrounding normal brain RT doses to improve median benchmark survival to 14-15 months as compared to the prevailing standard of care (40Gy/15# with temozolomide). The current trial plans to address this knowledge gap.

Primary Endpoint:

The primary endpoint will be the Overall Survival (OS) at 1 year. Overall Survival will be defined as the time elapsed from the date of randomization to date of death due to any cause.

Secondary Endpoint:

  • Progression Free Survival (PFS) at 1 year- Progression Free Survival will be defined as the time elapsed from the date of randomization to the date of clinico-radiological progression or death.
  • Toxicity assessment with the NCI Common Terminology Criteria for Adverse Events version 5 (CTCAE v5)
  • Quality of life indices using the EORTC QLQC- 30 and its BN -20 module
  • Quality of life without symptoms or toxicity in three health states TOX (toxicity), TWIST (time without symptoms) and REL (relapse)

Study Design:

The study will be a prospective, open-label2-arm Phase 2 randomized controlled trial with a superiority design. The standard arm will comprise of 3 week hypo-fractionated RT(40Gy/15#).The test arms will comprise of dose escalated hypo-fractionated RT (5 fractions/10 fractions). The usage of TMZ will be standard across both arms.

Study setting: The study will be conducted in the department of Radiation Oncology, Neuro Oncology Disease management group

03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven IDH- wild type GBM or imaging defined GBM
  • Neurological Predictor Scale (NPS) = 2-3
  • Unfit for surgery and referred for direct RT
  • Age >/= 50 years

Exclusion criteria

Exclusion Criteria:

  • IDH mutant glioma
  • Histone altered glioma
  • Multifocal disease or Gliomatosis like appearance which necessitates whole brain RT
  • Disseminated disease in brain or spine
  • NPS = 0-1 or = 4
  • Performance Status score less than 50(Patient requires considerable assistance and frequent medical care)
  • Prior administration of any systemic therapy directed against glioma (eg.Temozolomide, CCNU, Bevacizumab)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    Standard Arm

    The standard arm will comprise of 3 week hypo-fractionated RT(40Gy/15#).

    Radiation: Standard radiotherapy using hypofractionated RT

  • Experimental
    Dose-escalated hypofractionated RT

    Patients in the experimental arm will undergo pretreatment evaluation, MRI-based simulation, and radiotherapy delivery similar to the standard arm, with the addition of pre-treatment F-DOPA PET imaging performed according to institutional consensus protocols. Biological target volumes (BTVs) will be delineated using a tumor-to-white-matter uptake ratio \>2.0. The initial clinical target volume (CTV-initial) will include the BTV, postoperative cavity, contrast-enhancing tumor on T1-weighted MRI, and gross disease. A 1.5-cm margin, edited for anatomical barriers, will generate the CTV-final to account for infiltrative spread. The planning target volume (PTV) will be created using a 3-5-mm geometric expansion. Dose prescription will be based on PTV volume and location. Patients with PTV \>30 cc or tumors not involving the brainstem will receive 40 Gy in 10 fractions to the BTV and 35 Gy in 10 fractions to the PTV. Those with PTV ≤30 cc or brainstem involvement will receive 30 Gy in 5 fra

    Radiation: Experimental Arm Intervention

Interventions

  • RadiationStandard radiotherapy using hypofractionated RT

    Patients in the standard arm will undergo target volume delineation using conventional imaging. The initial clinical target volume (CTV-initial) will include the postoperative cavity, contrast-enhancing tumor on T1-weighted MRI, and gross disease. A 1-cm isotropic expansion, edited for anatomical barriers, will generate the CTV-final to account for infiltrative spread. The planning target volume (PTV) will be created using a 3-mm geometric margin for setup uncertainty. Radiotherapy will be delivered using photon-based image-guided IMRT, prescribed to a total dose of 40 Gy in 15 fractions, administered five days per week.

  • RadiationExperimental Arm Intervention

    Patients in the experimental arm will undergo pretreatment evaluation, MRI-based simulation, and radiotherapy delivery similar to the standard arm, with the addition of pre-treatment F-DOPA PET imaging performed according to institutional consensus protocols. Biological target volumes (BTVs) will be delineated using a tumor-to-white-matter uptake ratio \>2.0. The initial clinical target volume (CTV-initial) will include the BTV, postoperative cavity, contrast-enhancing tumor on T1-weighted MRI, and gross disease. A 1.5-cm margin, edited for anatomical barriers, will generate the CTV-final to account for infiltrative spread. The planning target volume (PTV) will be created using a 3-5-mm geometric expansion. Dose prescription will be based on PTV volume and location. Patients with PTV \>30 cc or tumors not involving the brainstem will receive 40 Gy in 10 fractions to the BTV and 35 Gy in 10 fractions to the PTV. Those with PTV ≤30 cc or brainstem involvement will receive 30 Gy in 5 frac

06

What researchers measure

Primary outcomes

  1. Survival Outcomes

    . Overall Survival will be defined as the time elapsed from the date of randomization to date of death due to any cause.

    Time frame: 1 year

Secondary outcomes

  1. Survival Outcome

    Progression Free Survival (PFS) will be defined as the time elapsed fromthe date of randomization to the date of clinico-radiological progression or death.

    Time frame: 1 year

  2. Quality of life indices- EORTC QLQC- 30

    Quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The scale scores are linearly transformed to a range of 0 to 100. For functional scales and global health status, higher scores indicate better quality of life; for symptom scales, higher scores indicate worse symptoms. Assessed at baseline and follow-up. Unit of Measure: Units on a scale

    Time frame: Baseline / Pre-radiotherapy, 4-6 weeks post-radiotherapy, 1 month, 3 months, 6 months, 9 months, and 12 months post-radiotherapy

  3. Quality of life indices- EORTC BN20

    Brain tumor-specific quality of life assessed using the European Organisation for Research and Treatment of Cancer Brain Neoplasm Module (EORTC QLQ-BN20). Scores are transformed to a range of 0 to 100, where higher scores indicate greater symptom burden (worse outcome). Assessed at baseline and follow-up. Unit of Measure: Units on a scale

    Time frame: Baseline / Pre-radiotherapy, 4-6 weeks post-radiotherapy, 1 month, 3 months, 6 months, 9 months, and 12 months post-radiotherapy

  4. QTWiST (Quality of life Without Symptoms or Toxicity) calculation

    QTWiST (Quality-Adjusted Time Without Symptoms or Toxicity) will be calculated by partitioning overall survival time into three mutually exclusive health states: TOX (time with treatment-related toxicity), TWiST (time without symptoms or toxicity), and REL (time after relapse/progression). The QTWiST value will be derived by applying utility weights to each health state and summing the weighted time spent in each state, expressed in months of quality-adjusted survival. Assessed at 3 months. Unit of Measure: Months (quality-adjusted survival time)

    Time frame: will be done at 3 months

  5. Toxicity Assessment

    Toxicity assessment with the NCI Common Terminology Criteria for Adverse Events version 5 (CTCAE v5)- Grade 1-5

    Time frame: Baseline / Pre-radiotherapy, 4-6 weeks post-radiotherapy, 1 month, 3 months, 6 months, 9 months, and 12 months post-radiotherapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2031, 71 months after the start.

Of 131 non-industry interventional studies with no phase under Glioma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 114. This study's planned 71 months is above that.

Counting every sponsor, half of 142 studies reached it within 58 months; a quarter within 34 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Jan 14, 2026
StartActual
Nov 6, 2025
Primary completionEst.
Oct 27, 2031
CompletionEst.
Oct 27, 2031
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07338539
Lead sponsor
Tata Memorial Centre
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Nov 6, 2025
Primary completion
Oct 27, 2031 (estimated)
Completion
Oct 27, 2031 (estimated)
Last update
May 18, 2026

Study contacts

Abhishek Chatterjee, MD
Contact
chatterji08@gmail.com
2224177000 ext. Ext. 6015

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion